Gold-doxorubicin nanoconjugates for overcoming multidrug resistance

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 8, Issue 2, 2012, Pages 204-211

  Gu, Yan Juan ^a   Cheng, Jinping ^a   Man, Cornelia Wing Yin ^b   Wong, Wing Tak ^b   Cheng, Shuk Han ^a  

^a CITY UNIVERSITY OF HONG KONG   (Hong Kong)

^b HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

Author keywords

Chemotherapy; Doxorubicin; Gold nanoparticles; Multidrug resistance

Indexed keywords

CHEMOTHERAPY; DISEASES; DRUG DELIVERY; DRUG DOSAGE; FIBER OPTIC SENSORS; INDUCTIVELY COUPLED PLASMA; MASS SPECTROMETRY; METAL NANOPARTICLES; NANOCONJUGATES; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; SULFUR COMPOUNDS;

ANTICANCER DRUG; CANCER CHEMOTHERAPY; CONFOCAL IMAGE; DISULFIDE LINKAGES; DOXORUBICIN; INDUCTIVELY COUPLED PLASMA MASS SPECTROSCOPIES; INTRACELLULAR UPTAKE; MULTIDRUG RESISTANCE;

GOLD NANOPARTICLES;

DISULFIDE; DOXORUBICIN; GOLD NANOPARTICLE; NANOCONJUGATE;

ARTICLE; CANCER CELL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG UPTAKE; HUMAN; HUMAN CELL; MASS SPECTROMETRY; MULTIDRUG RESISTANCE;

EID: 84860393608     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2011.06.005     Document Type: Article

References (42)

1. Cucco C., Calabretta B. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by MDR1 antisense oligonucleotides. Cancer Res 1996, 56:4332-4337.
2. Lage H. An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci 2008, 65:3145-3167.
3. Sakaeda T., Nakamura T., Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 2003, 4:397-410.
4. Cole S.P., Deeley R.G. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. Bioessays 1998, 20:931-940.
5. Leslie E.M., Deeley R.G., Cole S.P. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP(ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005, 204:216-237.
6. Pakunlu R.I., Wang Y., Tsao W., Pozharov V., Cook T.J., Minko T. Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: novel multicomponent delivery system. Cancer Res 2004, 64:6214-6224.
7. Yang X., Deng W., Fu L., Blanco E., Gao J., Quan D., et al. Folate-functionalized polymeric micelles for tumor targeted delivery of a potent multidrug-resistance modulator FG020326. J Biomed Mater Res A 2008, 86A:48-60.
8. Chavanpatil M.D., Khdair A., Gerard B., Bachmeier C., Miller D.W., Shekhar M.P.V., et al. Surfactant-polymer nanoparticles overcome P-glycoprotein-mediated drug efflux. Mol Pharm 2007, 4:730-738.
9. Sadava D., Coleman A., Kane S.E. Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells. J Liposome Res 2002, 12:301-309.
10. Lee S., Cha E.J., Park K., Lee S.Y., Hong J.K., Sun I.C., et al. A near-infrared-fluorescence-quenched gold-nanoparticle imaging probe for in vivo drug screening and protease activity determination. Angew Chem Int Ed Engl 2008, 47:1-5.
11. Yu A.M., Liang Z.J., Cho J.H., Caruso F. Nanostructured electrochemical sensor based on dense gold nanoparticle films. Nano Lett 2003, 3:1203-1207.
12. Chen Y.H., Tsai C.Y., Huang P.Y., Chang M.Y., Cheng P.C., Chou C.H., et al. Methotrexate conjugated to gold nanoparticles inhibits tumor growth in a syngeneic lung tumor model. Mol Pharm 2007, 4:713-722.
13. Podsiadlo P., Sinani V.A., Bahng J.H., Kam N.W.S., Lee J., Kotov N.A. Gold nanoparticles enhance the anti-leukemia action of a 6-mercaptopurine chemotherapeutic agent. Langmuir 2008, 24:568-574.
14. Frederick C.A., Williams L.D., Ughetto G., van der Marel G.A., van Boom J.H., Rich A., et al. Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin. Biochemistry 1990, 29:2538-2549.
15. Alberts D.S., Muggia F.M., Carmichael J., Winer E.P., Jahanzeb M., Venook A.P., et al. Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol 2004, 31:53-90.
16. Mamidi R.N.V.S., Weng S., Stellar S., Wang C., Yu N., Huang T., et al. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?. Cancer Chemother Pharmacol 2010, 66:1173-1184.
17. Batrakova E.V., Kelly D.L., Li S., Li Y., Yang Z., Xiao L., et al. Alteration of genomic responses to doxorubicin and prevention of MDR in breast cancer cells by a polymer excipient: pluronic P85. Mol Pharm 2006, 3:113-123.
18. Marchi N., Hallene K.L., Kight K.M., Cucullo L., Moddel G., Bingaman W., et al. Significance of MDR1 and multiple drug resistance in refractory human epileptic brain. Biomed Central Med 2004, 2:37-47.
19. Lee E.S., Na K., Bae Y.H. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J Control Release 2005, 103:405-418.
20. Greco F., Vicent M.J., Gee S., Gee A.T., Jones J., Nicholson R.I., et al. Investigating the mechanism of enhanced cytotoxicity of HPMA copolymer-Dox-AGM in breast cancer cells. J Control Release 2007, 117:28-39.
21. Tang N., Du G., Wang N., Liu C., Hang H., Liang W. Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin. J Natl Cancer Inst 2007, 99:1004-1015.
22. Theodossiou T.A., Galanou M.C., Paleos C.M. Novel amiodarone-doxorubicin cocktail liposomes enhance doxorubicin retention and cytotoxicity in DU145 human prostate carcinoma cells. J Med Chem 2008, 51:6067-6074.
23. Laginha K.M., Verwoert S., Charrois G.J.R., Allen T.M. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res 2005, 11:6944-6949.
24. Alakhov V.Y., Moskaleva E.Y., Batrakova E.V., Kabanov A.V. Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer. Bioconjug Chem 1996, 7:209-216.
25. Yoo H.S., Lee E.A., Park T.G. Doxorubicin-conjugated biodegradable polymeric micelles having acid-cleavable linkages. J Control Release 2002, 82:17-27.
26. Gu Y.J., Cheng J., Lin C.C., Lam Y.W., Cheng S.H., Wong W.T. Nuclear penetration of surface functionalized gold nanoparticles. Toxicol Appl Pharmacol 2009, 237:196-204.
27. Wang C., Zhang J.X., Shen X.L., Wan E.C.K., Tse K.W.N., Fong W.F. Reversal of P-glycoprotein-mediated multidrug resistance by alisol B 23-acetate. Biochem Pharmacol 2004, 68:843-855.
28. Fong W.F., Shen X.L., Globisch C., Wiese M., Chen G.Y., Zhu G.Y., et al. Methoxylation of 3',4'-aromatic side chains improves P-glycoprotein inhibitory and multidrug resistance reversal activities of 7,8-pyranocoumarin against cancer cells. Bioorg Med Chem 2008, 16:3694-3703.
29. Kam N.W.S., Liu Z., Dai H. Functionalization of carbon nanotubes via cleavable disulfide bonds for efficient intracellular delivery of siRNA and potent gene silencing. J Am Chem Soc 2005, 127:12492-12493.
30. Giri S., Trewyn B.G., Stellmaker M.P., Lin V.S.Y. Stimuli-responsive controlled-release delivery system based on mesoporous silica nanorods capped with magnetic nanoparticles. Angew Chem Int Ed Engl 2005, 44:5038-5044.
31. Zhou X., Chang Y.C., Oyama T., McGuire M.J., Brown K.C. Cell-specific delivery of a chemotherapeutic to lung cancer cells. J Am Chem Soc 2004, 126:15656-15657.
32. Albert B.J., McPherson P.A., O'Brien K., Czaicki N.L., DeStefino V., Osman S., et al. Meayamycin inhibits pre-messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells. Mol. Cancer Ther 2009, 8:2308-2318.
33. Prabaharan M., Grailer J.J., Pilla S., Steeber D.A., Gong S. Gold nanoparticles with a monolayer of doxorubicin-conjugated amphiphilic block copolymer for tumor-targeted drug delivery. Biomaterials 2009, 30:6065-6075.
34. Yoo H.S., Park T.G. Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate. J Control Release 2004, 100:247-256.
35. Li J., Wang X., Wang C., Chen B., Dai Y., Zhang R., et al. The enhancement effect of gold nanoparticles in drug delivery and as biomarkers of drug-resistant cancer cells. ChemMedChem 2007, 2:374-378.
36. Aryal S., Grailer J.J., Pilla S., Steeber D.A., Gong S. Doxorubicin conjugated gold nanoparticles as water-soluble and pH-responsive anticancer drug nanocarriers. J Mater Chem 2009, 19:7879-7884.
37. Satyam A. Design and synthesis of releasable folate-drug conjugates using a novel heterobifunctional disulfide-containing linker. Bioorg Med Chem Lett 2008, 18:3196-3199.
38. Ellis C.N., Ellis M.B., Blakemore W.S. Effect of adriamycin on heart mitochondrial DNA. Biochem J 1987, 245:309-312.
39. Lampidis T.J., Hasin Y., Weiss M.J., Chen L.B. Selective killing of carcinoma cells "in vitro" by lipophilic-cationic compounds: a cellular basis. Biomed Pharmacother 1985, 39:220-226.
40. Gupta R., Guralnik G., Kilcup G.W., Patel A., Sharpe S.R. Clear evidence for a first-order chiral transition in QCD. Phys Rev Lett 1986, 57:2621-2624.
41. Abraham S.A., Waterhouse D.N., Mayer L.D., Cullis P.R., Madden T.D., Bally M.B. The liposomal formulation of doxorubicin. Methods Enzymol 2005, 391:71-97.
42. Koktorovova S., Souto E.B. Nanostructured lipid carrier-based hydrogel formulation for drug delivery: a comprehensive review. Expert Opin Drug Del 2009, 6:165-167.